NCT05799157View on ClinicalTrials.gov

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

PHASE2CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

February 25, 2025

Study Completion Date

February 25, 2025

Conditions
Verruca VulgarisWartsCommon Wart
Interventions
DRUG

VDMN-21 Patch Low Dose

Microneedle patch containing 125 mcg of active drug

DRUG

VDMN-21 Patch High Dose

Microneedle patch containing 250 mcg of active drug

DRUG

Vehicle Patch

Placebo microneedle patch containing no active drug (i.e., placebo)

Trial Locations (16)

23502

Site 14, Norfolk

29615

Site 06, Greenville

29621

Site 01, Anderson

37909

Site 11, Knoxville

40241

Site 13, Louisville

46168

Site 02, Plainfield

55112

Site 09, New Brighton

70809

Site 15, Baton Rouge

72916

Site 07, Fort Smith

76011

Site 03, Arlington

77056

Site 12, Houston

77845

Site 10, College Station

78660

Site 05, Pflugerville

78759

Site 04, Austin

92123

Site 16, San Diego

99202

Site 08, Spokane

All Listed Sponsors
lead

Veradermics, Inc.

INDUSTRY